

STEP THERAPY CRITERIA

BRAND NAME

(generic)

TREXIMET

(sumatriptan/naproxen)

Status: CVS Caremark Criteria

Type: Initial Step Therapy; Post Step Therapy Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Treximet is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older.

Use only if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with Treximet, reconsider the diagnosis of migraine before Treximet is administered to treat any subsequent attacks. Treximet is not indicated for the prevention of migraine attacks. Safety and effectiveness of Treximet have not been established for cluster headache.

INITIAL STEP THERAPY*

**Include Rx and OTC products unless otherwise stated.*

If the patient has filled a prescription for at least a 30 day supply of generic sumatriptan AND generic naproxen within the past 120 days under a prescription benefit administered by CVS Caremark, then the requested drug will be paid under that prescription benefit. If the patient does not meet the initial step therapy criteria, then the claim will reject with a message indicating that a prior authorization (PA) is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The patient has a diagnosis of migraine headache

AND

- The patient has tried and experienced an inadequate treatment response or intolerance to THREE 5-HT₁ agonists (triptans)

AND

- The patient has tried sumatriptan taken with naproxen

REFERENCES

1. Treximet [package insert]. Morristown, NJ: Pernix Therapeutics, LLC; November 2017.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. <http://online.lexi.com/>. Accessed June 2019.
3. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. <http://www.micromedexsolutions.com/>. Accessed June 2019.
4. Beithon J, Gallenberg M, Johnson K, et al. Institute for Clinical Systems Improvement. Diagnosis and Treatment of Headache. https://www.icsi.org/_asset/qwrznq/Headache.pdf. Updated January 2013. Accessed May 2016.
5. American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. *Headache* 2019;59:1-18.